天堂网亚洲,天天操天天搞,91视频高清,菠萝蜜视频在线观看入口,美女视频性感美女视频,95丝袜美女视频国产,超高清美女视频图片

Home Cart 0 Sign in  

[ CAS No. 33419-42-0 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 33419-42-0
Chemical Structure| 33419-42-0
Structure of 33419-42-0 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 33419-42-0 ]

Related Doc. of [ 33419-42-0 ]

Alternatived Products of [ 33419-42-0 ]
Product Citations

Product Citations

Andressa Santana?Santos ; Vinícius Alexandre Fiaia?Costa ; Vivianny Aparecida Queiroz?Freitas , et al. DOI: PubMed ID:

Abstract: Sporotrichosis is recognized as the predominant subcutaneous mycosis in South America, attributed to pathogenic species within the Sporothrix genus. Notably, in Brazil, Sporothrix brasiliensis emerges as the principal species, exhibiting significant sapronotic, zoonotic and enzootic epidemic potential. Consequently, the discovery of novel therapeutic agents for the treatment of sporotrichosis is imperative. The present study is dedicated to the repositioning of pharmaceuticals for sporotrichosis therapy. To achieve this goal, we designed a pipeline with the following steps: (a) compilation and preparation of Sporothrix genome data; (b) identification of orthologous proteins among the species; (c) identification of homologous proteins in publicly available drug-target databases; (d) selection of Sporothrix essential targets using validated genes from Saccharomyces cerevisiae; (e) molecular modeling studies; and (f) experimental validation of selected candidates. Based on this approach, we were able to prioritize eight drugs for in vitro experimental validation. Among the evaluated compounds, everolimus and bifonazole demonstrated minimum inhibitory concentration (MIC) values of 0.5 μg/mL and 4.0 μg/mL, respectively. Subsequently, molecular docking studies suggest that bifonazole and everolimus may target specific proteins within S. brasiliensis– namely, sterol 14-α-demethylase and serine/threonine-protein kinase TOR, respectively. These findings shed light on the potential binding affinities and binding modes of bifonazole and everolimus with their probable targets, providing a preliminary understanding of the antifungal mechanism of action of these compounds. In conclusion, our research advances the understanding of the therapeutic potential of bifonazole and everolimus, supporting their further investigation as antifungal agents for sporotrichosis in prospective hit-to-lead and preclinical investigations.

Keywords: Sporotrichosis ; Sporothrix brasiliensis ; Drug repurposing ; Structural bioinformatics ; Everolimus

Purchased from AmBeed: ; ; ; ;

Product Details of [ 33419-42-0 ]

CAS No. :33419-42-0 MDL No. :
Formula : C29H32O13 Boiling Point : -
Linear Structure Formula :- InChI Key :VJJPUSNTGOMMGY-MRVIYFEKSA-N
M.W : 588.56 Pubchem ID :36462
Synonyms :
VP-16;VP-16-213;Demethyl Epipodophyllotoxin Ethylidine Glucoside. epipodophyllotoxin. US brand names: Toposar. VePesid. Foreign brand name: Lastet. Abbreviation: EPEG Code names: VP16;VP-16-123;NSC 141540;EPE
Chemical Name :(5R,5aR,8aR,9S)-9-(((4aR,6R,7R,8R,8aS)-7,8-Dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one

Calculated chemistry of [ 33419-42-0 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 42
Num. arom. heavy atoms : 12
Fraction Csp3 : 0.55
Num. rotatable bonds : 5
Num. H-bond acceptors : 13.0
Num. H-bond donors : 3.0
Molar Refractivity : 139.11
TPSA : 160.83 ?2

Pharmacokinetics

GI absorption : Low
BBB permeant : No
P-gp substrate : Yes
CYP1A2 inhibitor : No
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : Yes
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -9.46 cm/s

Lipophilicity

Log Po/w (iLOGP) : 3.24
Log Po/w (XLOGP3) : 0.6
Log Po/w (WLOGP) : 1.01
Log Po/w (MLOGP) : -0.14
Log Po/w (SILICOS-IT) : 0.95
Consensus Log Po/w : 1.13

Druglikeness

Lipinski : 2.0
Ghose : None
Veber : 1.0
Egan : 1.0
Muegge : 2.0
Bioavailability Score : 0.17

Water Solubility

Log S (ESOL) : -3.75
Solubility : 0.105 mg/ml ; 0.000178 mol/l
Class : Soluble
Log S (Ali) : -3.55
Solubility : 0.165 mg/ml ; 0.000281 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.18
Solubility : 0.385 mg/ml ; 0.000655 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 0.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 6.27

Safety of [ 33419-42-0 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P261-P305+P351+P338 UN#:N/A
Hazard Statements:H302-H315-H319-H335-H351-H361 Packing Group:N/A
GHS Pictogram:
Recommend Products
Same Skeleton Products
Historical Records

Similar Product of
[ 33419-42-0 ]

Chemical Structure| 117091-64-2

A663953[ 117091-64-2 ]

Etoposide phosphate

Reason: Free-salt

; ;